AR132404A1 - Compuestos dirigidos a steap2 y uso de los mismos - Google Patents
Compuestos dirigidos a steap2 y uso de los mismosInfo
- Publication number
- AR132404A1 AR132404A1 ARP240100916A ARP240100916A AR132404A1 AR 132404 A1 AR132404 A1 AR 132404A1 AR P240100916 A ARP240100916 A AR P240100916A AR P240100916 A ARP240100916 A AR P240100916A AR 132404 A1 AR132404 A1 AR 132404A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- steap2
- pharmaceutically acceptable
- acceptable salts
- present disclosure
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente divulgación proporciona compuestos o sales farmacéuticamente aceptables de los mismos, por ejemplo, radioinmunoconjugados que incluyen una porción quelante o un complejo metálico de la misma, un ligador y un anticuerpo o fragmento de unión a antígeno del mismo que se dirige a STEAP2. La presente divulgación también proporciona composiciones farmacéuticas de estos compuestos o sales farmacéuticamente aceptables de los mismos y métodos de tratamiento para condiciones, por ejemplo, cáncer, usando estos compuestos, sales farmacéuticamente aceptables de los mismos o composiciones farmacéuticas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363495561P | 2023-04-12 | 2023-04-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR132404A1 true AR132404A1 (es) | 2025-06-25 |
Family
ID=91076806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240100916A AR132404A1 (es) | 2023-04-12 | 2024-04-11 | Compuestos dirigidos a steap2 y uso de los mismos |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240350682A1 (es) |
| EP (1) | EP4694940A1 (es) |
| JP (1) | JP2026515739A (es) |
| KR (1) | KR20250168673A (es) |
| CN (1) | CN120936390A (es) |
| AR (1) | AR132404A1 (es) |
| AU (1) | AU2024250505A1 (es) |
| CL (1) | CL2025003080A1 (es) |
| CO (1) | CO2025015456A2 (es) |
| CR (1) | CR20250479A (es) |
| IL (1) | IL323857A (es) |
| MX (1) | MX2025012115A (es) |
| TW (1) | TW202506205A (es) |
| WO (1) | WO2024215948A1 (es) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| MX387295B (es) | 2015-03-31 | 2025-03-18 | Medimmune Ltd | Nueva forma de interleucina-33 (il33), formas mutadas de interleucina-33 (il33), anticuerpos, ensayos y métodos para usar los mismos. |
| DE102016114470A1 (de) | 2016-08-04 | 2018-02-08 | Landscaper Service & Design Gmbh | Flexibler Schüttgutbehälter |
| KR102520731B1 (ko) * | 2016-09-23 | 2023-04-14 | 리제너론 파아마슈티컬스, 인크. | 항-steap2 항체, 항체-약물 컨쥬게이트, 및 steap2 및 cd3에 결합하는 이중특이적 항원-결합 분자, 및 이의 용도 |
| IL312003A (en) * | 2021-10-15 | 2024-06-01 | Astrazeneca Ab | Chimeric ANTI-STEAP2 receptors and their uses |
-
2024
- 2024-04-11 US US18/633,413 patent/US20240350682A1/en active Pending
- 2024-04-11 AR ARP240100916A patent/AR132404A1/es unknown
- 2024-04-11 AU AU2024250505A patent/AU2024250505A1/en active Pending
- 2024-04-11 WO PCT/US2024/024155 patent/WO2024215948A1/en not_active Ceased
- 2024-04-11 KR KR1020257037734A patent/KR20250168673A/ko active Pending
- 2024-04-11 CN CN202480025046.0A patent/CN120936390A/zh active Pending
- 2024-04-11 EP EP24725657.1A patent/EP4694940A1/en active Pending
- 2024-04-11 TW TW113113636A patent/TW202506205A/zh unknown
- 2024-04-11 JP JP2025559494A patent/JP2026515739A/ja active Pending
- 2024-04-11 CR CR20250479A patent/CR20250479A/es unknown
-
2025
- 2025-10-09 CL CL2025003080A patent/CL2025003080A1/es unknown
- 2025-10-09 IL IL323857A patent/IL323857A/en unknown
- 2025-10-10 MX MX2025012115A patent/MX2025012115A/es unknown
- 2025-11-06 CO CONC2025/0015456A patent/CO2025015456A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202506205A (zh) | 2025-02-16 |
| EP4694940A1 (en) | 2026-02-18 |
| JP2026515739A (ja) | 2026-05-19 |
| CR20250479A (es) | 2026-05-26 |
| CN120936390A (zh) | 2025-11-11 |
| MX2025012115A (es) | 2025-11-03 |
| CL2025003080A1 (es) | 2026-01-16 |
| AU2024250505A1 (en) | 2025-11-27 |
| KR20250168673A (ko) | 2025-12-02 |
| IL323857A (en) | 2025-12-01 |
| CO2025015456A2 (es) | 2025-11-19 |
| US20240350682A1 (en) | 2024-10-24 |
| WO2024215948A1 (en) | 2024-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY38700A (es) | Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso | |
| MX2021002804A (es) | Terapias de combinacion. | |
| MX2024008551A (es) | Terapias de combinacion. | |
| PE20241582A1 (es) | Anticuerpos lrrc15 y conjugaddos de los mismos | |
| PE20211412A1 (es) | Anticuerpos anti-gdf15, composiciones y metodos de uso | |
| MX2020011868A (es) | Inhibidores de los receptores erbb. | |
| CL2024002658A1 (es) | Moléculas de unión contra fralfa | |
| MX2020007947A (es) | Inhibidores de erbb/btk. | |
| MX2022004582A (es) | Anticuerpo humanizado marcado con ri. | |
| CL2021001607A1 (es) | Anticuerpos anti-pmel17 y conjugados de los mismos | |
| DOP2024000245A (es) | Conjugados de anticuerpo-fármaco de compuestos antineoplásicos y métodos de uso de los mismos | |
| MX2022001133A (es) | Regimen de dosificacion para un inhibidor de indolamina 2,3-dioxigenasa (ido). | |
| AR129382A1 (es) | Conjugados de anticuerpo-fármaco inhibidores de bcl-xl y met y sus métodos de uso | |
| CO2024003299A2 (es) | Conjugado anticuerpo-fármaco anti-cd37 | |
| CO2026002111A2 (es) | Anticuerpos gucy2c y usos de estos | |
| DOP2025000285A (es) | Inhibidores de ciclina | |
| CO2021017477A2 (es) | Terapia de combinación | |
| MX2025012115A (es) | Compuestos dirigidos al antigeno epitelial de seis transmembranas de la prostata 2 (steap2) y uso de los mismos | |
| AR122411A1 (es) | Radioinmunoconjugados dirigidos a tem-1 y sus usos | |
| CL2022002557A1 (es) | Radioinmunoconjugados dirigidos a fgfr3 y usos de estos | |
| CL2024001656A1 (es) | Conjugado que comprende amatoxina y un resto de unión a cd20. | |
| UY39662A (es) | Inhibidores de egfr | |
| PY24103378A (es) | Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos | |
| CL2025001474A1 (es) | Anticuerpos anti-cd137 y métodos de uso | |
| AR122660A2 (es) | Anticuerpos anti-pmel17 y conjugados de los mismos |